The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Official Title: Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Whose Disease Did Not Progress After Completion of First-line Durvalumab Combined With Gemcitabine+Cisplatin Treatment
Study ID: NCT06255262
Brief Summary: A Real-World Study of Durvalumab combined with Surufatinib as maintenance therapy in patients with advanced biliary tract cancer whose disease did not progress after completion of first-line Durvalumab combined with Gemcitabine+cisplatin treatment.
Detailed Description: This is a single-arm, multicentre real-world study of Durvalumab combined with Surufatinib as maintenance therapy in patients with advanced biliary tract cancer whose disease did not progress after completion of first-line Durvalumab combined with Gemcitabine+cisplatin treatment.The primary purpose of the study is exploring the efficacy and safety of durvalumab in combination with surufatinib for the maintenance therapy of patients with advanced biliary tract cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Anshan Cancer Hospital, Anshan, Liaoning, China
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
First Hospital of China Medical University, Shenyang, Liaoning, China
Shenyang Fifth People's Hospital, Shenyang, Liaoning, China
Name: Yunpeng Liu, PhD
Affiliation: First Hospital of China Medical University
Role: PRINCIPAL_INVESTIGATOR
Name: Xiujuan Qu, PhD
Affiliation: First Hospital of China Medical University
Role: PRINCIPAL_INVESTIGATOR